Healthcare Industry News: paclitaxel
News Release - May 22, 2007
SPIRIT Clinical Data Reaffirm Strength of TAXUS(R) and PROMUS(TM) Drug-Eluting Coronary Stent SystemsSPIRIT FIRST follow-up analysis shows no stent thrombosis or MACE after one year
NATICK, Mass. and BARCELONA, Spain, May 22 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the results of additional data from the SPIRIT FIRST, II and III Clinical Trials, reaffirming prior safety and efficacy data for the market-leading TAXUS® Express2(TM) paclitaxel-Eluting Coronary Stent System and XIENCE(TM) V (PROMUS(TM)) Everolimus Eluting Coronary Stent System. The PROMUS Stent is a private- labeled XIENCE(TM) V Stent, manufactured by Abbott and distributed by Boston Scientific. Boston Scientific is the only company to offer the choice of two distinct drug-eluting stent platforms.
The data were presented by Gregg W. Stone, M.D., Chairman and Chief Medical Officer of the Cardiovascular Research Foundation, Columbia University Medical Center, New York City, at the annual Paris Course on Revascularization (EuroPCR) in Barcelona.
The SPIRIT FIRST three-year clinical follow-up results provided further support for the safety and efficacy of the XIENCE V (PROMUS) Stent, with no additional MACE since one-year follow up. In addition, no acute, sub-acute or late stent thrombosis was seen in either the XIENCE V (PROMUS) or BMS control group through three years.
Dr. Stone's presentation also included results of a pooled analysis of previously reported SPIRIT II and III data, where stent thrombosis rates were shown to be very low for both stents (0.45 percent for the XIENCE V (PROMUS) Stent and 0.25 percent for the TAXUS Stent, p=0.59).
"It is reassuring to see that both stents performed exceptionally well in the SPIRIT Clinical Trials on multiple safety measures including stent thrombosis," said Jeff Goodman, President of International for Boston Scientific. "The data for these two drug-eluting stent platforms continue to reinforce Boston Scientific's leadership position in drug-eluting stent technologies. We also look forward to Abbott presenting and publishing subset data from the SPIRIT Clinical Trials."
The PROMUS Stent has CE Mark approval and is distributed in most European countries and other international markets. The XIENCE V (PROMUS) Everolimus Eluting Coronary Stent System is an investigational device in the U.S. and not yet approved for sale. It is currently under FDA review with an anticipated U.S. launch in 2008.
SPIRIT is sponsored by Abbott. TAXUS, Express2 and PROMUS are trademarks of Boston Scientific Corporation or its affiliates. XIENCE is a trademark of Abbott Laboratories group of companies.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBoston Scientific Exercises Option to Acquire Farapulse, Inc.
Boston Scientific Completes CE Mark for EXALT(TM) Model B Single-Use Bronchoscope
Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2(TM) Aortic Valve System